1-benzyl-4-(isoquinoline-5-sulfonyl)piperazine-2-carboxylic acid ethyl ester | 842135-90-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-benzyl-4-(isoquinoline-5-sulfonyl)piperazine-2-carboxylic acid ethyl ester
• 英文别名: 1-benzyl-4-(isoquinoline-5-sulphonyl)-piperazine-2-carboxylic acid ethyl ester；Ethyl 1-benzyl-4-isoquinolin-5-ylsulfonylpiperazine-2-carboxylate
• CAS: 842135-90-4
• 化学式: C₂₃H₂₅N₃O₄S
• 分子量: 439.535
• InChiKey: CZVYGGRQZVERFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  604.7±65.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  88.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-(isoquinoline-5-sulfonyl)piperazine-2-carboxylic acid ethyl ester 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.5h， 生成 5-[4-benzyl-3-(4-chlorobenzyloxymethyl)-piperazine-1-sulfonyl]-isoquinoline
  参考文献：
  名称：

  蛋白激酶B的异喹啉5磺酰胺抑制剂的基于结构的设计。

  摘要：

  研究了新型PKB异喹啉5磺酰胺抑制剂作为潜在抗肿瘤药的基于结构的药物设计。鉴定并模拟了线性原型的结合构象的约束吡咯烷类似物，并通过与相关蛋白PKA的共晶体结构测定进行了研究。观察到具有相似总体构象的抑制剂之间结合模式的详细变化。该系列中的强效PKB抑制剂在细胞测定中抑制GSK3beta磷酸化，与细胞中PKB激酶活性的抑制一致。

  DOI：

  10.1016/j.bmc.2005.09.055
• 作为产物：
  描述：

  1-苄基哌嗪-2-羧酸乙酯 、 异喹啉-5-磺酰氯盐酸盐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.75h， 以57%的产率得到1-benzyl-4-(isoquinoline-5-sulfonyl)piperazine-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] SULFONAMIDE DERIVATIVES WITH ACTIVITY ON PROTEIN KINASE A AND B
  [FR] COMPOSES PHARMACEUTIQUES

  摘要：

  公开号：

  WO2005011697A3

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005011697A2

  公开（公告）日：2005-02-10

  The invention provides compounds for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A or protein kinase B, the compounds having the formula (I°), or being salts or solvates thereof. In formula (I°), n is 0 or 1; A and E are alkylene 2-3 carbon atoms in length optionally substituted by R11 and -X-CH(R6)(R7); G is hydrogen when n is 0 and, when n is 1, G is hydrogen or -X-CH(R6)(R7); R1 is an aryl or heteroaryl group having 5-12 ring members; R2 and R4 are selected from hydrogen, R7, R11 and CH(R6)(R7); R3, R3a and R5 are selected from hydrogen, R11 and -X-CH(R6)(R7); or any one pair or any two non-overlapping pairs selected from R2 and R3; R3 and R4; R2 and R5; R3 and R5; R4 and R5; R3 and R8; and R4 and R8 are linked together in a ring and together form an alkylene chain of 1-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or the pair R2 and R4 are linked together in a ring and together form an alkylene chain of 2-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); and optionally R3 and R3a may be linked together in a ring and together form an alkylene chain of 1-6 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or R6 and R7 together with the carbon atom to which they are attached form a cyclic group having 5-12 ring members; X, R6, R7, R8, R9, R10 and R11 are each as defined in claim 1; and wherein the definitions of, A, E, G, X, n and R1 to R11 are subject to the provisos set ou in claim 1.
• Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B
  作者：Ian Collins、John Caldwell、Tatiana Fonseca、Alastair Donald、Vassilios Bavetsias、Lisa-Jane K. Hunter、Michelle D. Garrett、Martin G. Rowlands、G. Wynne Aherne、Thomas G. Davies、Valerio Berdini、Steven J. Woodhead、Deborah Davis、Lisa C.A. Seavers、Paul G. Wyatt、Paul Workman、Edward McDonald

  DOI：10.1016/j.bmc.2005.09.055

  日期：2006.2

  Structure-based drug design of novel isoquinoline-5-sulfonamide inhibitors of PKB as potential antitumour agents was investigated. Constrained pyrrolidine analogues that mimicked the bound conformation of linear prototypes were identified and investigated by co-crystal structure determinations with the related protein PKA. Detailed variation in the binding modes between inhibitors with similar overall

  研究了新型PKB异喹啉5磺酰胺抑制剂作为潜在抗肿瘤药的基于结构的药物设计。鉴定并模拟了线性原型的结合构象的约束吡咯烷类似物，并通过与相关蛋白PKA的共晶体结构测定进行了研究。观察到具有相似总体构象的抑制剂之间结合模式的详细变化。该系列中的强效PKB抑制剂在细胞测定中抑制GSK3beta磷酸化，与细胞中PKB激酶活性的抑制一致。
• [EN] SULFONAMIDE DERIVATIVES WITH ACTIVITY ON PROTEIN KINASE A AND B<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005011697A3

  公开（公告）日：2005-04-21